Unknown

Dataset Information

Structural Insights and Development of LRRK2 Inhibitors for Parkinson's Disease in the Last Decade.


ABSTRACT: Parkinson's disease (PD) is the second most prevalent neurodegenerative disease, characterized by the specific loss of dopaminergic neurons in the midbrain. The pathophysiology of PD is likely caused by a variety of environmental and hereditary factors. Many single-gene mutations have been linked to this disease, but a significant number of studies indicate that mutations in the gene encoding leucine-rich repeat kinase 2 (LRRK2) are a potential therapeutic target for both sporadic and familial forms of PD. Consequently, the identification of potential LRRK2 inhibitors has been the focus of drug discovery. Various investigations have been conducted in academic and industrial organizations to investigate the mechanism of LRRK2 in PD and further develop its inhibitors. This review summarizes

SUBMITTER: Thakur G 

PROVIDER: S-EPMC9408223 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature